ライフサイエンスコーパス: oligonucleotide

1 in with a well-tolerated dose of the inducer oligonucleotide.

2 tly regulated by a steric-blocking antisense oligonucleotide.

3 toadduct using the 5'-TT(4tT)T(4tT)TT-3' DNA oligonucleotide.

4 ed when the protein is removed as part of an oligonucleotide.

5 ease in the context of a terminally modified oligonucleotide.

6 of long oligonucleotides using short splint oligonucleotides.

7 probe by conjugating negatively charged DNA oligonucleotides.

8 degradable delivery platform for therapeutic oligonucleotides.

9 voiding ribozyme inhibition by complementary oligonucleotides.

10 ribozyme by the templated ligation of short oligonucleotides.

11 are competitive strand displacement between oligonucleotides.

12 ments and implemented for ligands coupled to oligonucleotides.

13 nipulation and gene silencing with antisense oligonucleotides.

14 organs revealed no pronounced toxicity of u-oligonucleotides.

15 morpholinos, to create morpholino-pS hybrid oligonucleotides.

16 -stranded DNA as compared to single-stranded oligonucleotides.

17 eting of all possible candidate CRISPR guide oligonucleotides.

18 are natural biopolymers such as peptides and oligonucleotides.

19 h, three base-mismatch and non-complementary oligonucleotides.

20 used by elongation of the short ICL-unhooked oligonucleotide (a six-mer in our study) by Pol eta prov

21 include phosphorothioated cytosine-guanosine oligonucleotides, a motif often seen in bacterial or vir

22 renewed and growing interest in therapeutic oligonucleotides across the pharmaceutical industry, pre

23 ied the development of greener processes for oligonucleotide Active Pharmaceutical Ingredients (APIs)

24 demonstrated that microRNA miR-21-targeted u-oligonucleotides administered in complex with folate-con

25 linking of leaf tissue followed by antisense oligonucleotide affinity capture of psbA mRNA; and (ii)

26 s received the hepatocyte-directed antisense oligonucleotide AKCEA-APO(a)-L(Rx), referred to here as

27 Systemic administration of C-miR146a oligonucleotide alleviated human monocyte-dependent rele

28 H in a controlled complex system of ~262,000 oligonucleotides already reduces sequencing depth by a f

29 minary biochemical characterization of a new oligonucleotide analogue called thiophosphoramidate morp

30 cs of association of a labeled complementary oligonucleotide and a target analyte, l-tyrosinamide (L-

31 ck-translation to produce nuclease-resistant oligonucleotides and 3'-terminal transferase tailing.

32 are present predominantly as single-stranded oligonucleotides and are suitable substrates for Cdc13.

33 sign is cost-efficient because it uses short oligonucleotides and does not require conjugation of org

34 l antibodies, protein replacement therapies, oligonucleotides and gene and cell therapies, as well as

35 erexpression were undertaken using antisense oligonucleotides and overexpression plasmids.

36 uating the pressure effect on separations of oligonucleotides and proteins on an anion exchange colum

37 sses of agents have been developed-antisense oligonucleotides and small interfering RNA.

38 the structural and biophysical properties of oligonucleotides and their complexes.

39 signaling systems (CBASS) that sense cyclic oligonucleotides and transmit the signal to an effector

40 d by their hybridization to a "truth marker" oligonucleotide, and only true messages can be read; bin

41 for concentrating dendritic cells (DCs), CpG oligonucleotides, and a doxorubicin-iRGD conjugate enhan

42 f mRNA, short interfering RNAs (siRNAs), DNA oligonucleotides, and dextrans of sizes ranging from 6 k

43 e of true message- and false message-encoded oligonucleotides, and enables rapid and permanent erasur

44 ion (NETD) has proven valuable in sequencing oligonucleotide anions, particularly because it can reta

45 Oligonucleotide aptamers can be converted into structure

46 This method uses DNA oligonucleotide aptamers that bind either to a specific

47 res as model systems to demonstrate that DNA oligonucleotides are amenable to in-solution HDX/MS in n

48 First, biotinylated adapter oligonucleotides are hybridized to the DNA fragment.

49 Therapeutic oligonucleotides are often modified using the phosphorot

50 er analogous to yeast and humans in a 25-mer oligonucleotide arising from incisions at 15 nt from the

51 Using oligonucleotide arrays, we found that pDC-MM interaction

52 tudy of systemic treatment with an antisense oligonucleotide (ASO) (ISIS 486178) targeted to a non-CU

53 Antisense oligonucleotide (ASO) drugs that trigger RNase H1 cleava

54 high sensitivity identification of antisense oligonucleotide (ASO) impurities using a Q-Exactive mass

55 croinjection of a splice-switching antisense oligonucleotide (ASO) into the amniotic cavity immediate

56 ing treatment of SCA2 mice with an antisense oligonucleotide (ASO) lowering ATXN2 expression.

57 an be effectively treated using an antisense oligonucleotide (ASO) that induces exon skipping to rest

58 In this study, we utilized an antisense oligonucleotide (ASO) to reduce IDOL expression therapeu

59 Conjugation of antisense oligonucleotide (ASO) with a variety of distinct lipophi

60 ce of the Scn8a transcript with an antisense oligonucleotide (ASO) would delay seizure onset and prol

61 Nusinersen, a splice-switching antisense oligonucleotide (ASO), was the first approved drug to tr

62 We recently showed that antisense oligonucleotide (ASO)-mediated PrP suppression extends s

63 cutaneous administration of Notch2 antisense oligonucleotides (ASO) down-regulates Notch2 and the Not

64 Matrix metalloproteinase 9 (MMP-9) antisense oligonucleotides (ASO) or an MMP inhibitor were used to

65 o improve the productive uptake of antisense oligonucleotides (ASO), we synthesized neurotensin-ASO c

66 rgeting 2'-O-methyl (2'OMe) gapmer antisense oligonucleotides (ASOs) can have opposing activities on

67 PS chirality on the performance of antisense oligonucleotides (ASOs) has been a subject of debate for

68 Antisense oligonucleotides (ASOs) have been under intense investig

69 Splice-switching antisense oligonucleotides (ASOs) have emerged as an effective the

70 Antisense oligonucleotides (ASOs) interact with target RNAs via hy

71 ious treatments available for DMD, antisense oligonucleotides (ASOs) mediated exon skipping is a prom

72 gene expression is via the use of antisense oligonucleotides (ASOs) that harness the RNase H1 mechan

73 Antisense oligonucleotides (ASOs) that trigger RNase-H-mediated cl

74 V NA-based technologies, including antisense oligonucleotides (ASOs), siRNAs, RNA-targeting clustered

75 Using non-cleaving antisense oligonucleotides (ASOs), we selectively blocked CGG RAN.

76 Splice-switching antisense oligonucleotides (ASOs), which bind specific RNA-target

77 ucleic acid-based drugs, including antisense oligonucleotides (ASOs).

78 and pharmacodynamic properties of antisense oligonucleotides (ASOs).

79 g hepcidin activators like Tmprss6-antisense oligonucleotides [ASOs]) or increase erythropoiesis (by

80 s of DNA brick nanostructures with dendritic oligonucleotides attached to the outer surface.

81 leic acids are predominantly captured by one oligonucleotide barcode.

82 ds may contain detectable levels of multiple oligonucleotide barcodes.

83 riophage defense system termed CBASS (cyclic oligonucleotide-based anti-phage signaling system).

84 domains (SAVED) are key components of cyclic oligonucleotide-based antiphage signaling systems (CBASS

85 We developed oligonucleotide-based chromosome painting probes for all

86 Here, we provide an overview of oligonucleotide-based drug platforms, focusing on key ap

87 Indeed, antisense oligonucleotide-based exon skipping has shown promise fo

88 copy of chromosome 10 in the materials using oligonucleotide-based haplotype-specific chromosome pain

89 ques for the detection of COVID-19 including oligonucleotide-based molecular detection, Point-of-Care

90 sues with limited epitope retention and with oligonucleotide-based staining, allowing potential cross

91 More broadly, we demonstrate that oligonucleotide-based therapeutic agents can be delivere

92 Oligonucleotide-based therapeutics have become a reality

93 Although both small molecule-based and oligonucleotide-based therapies have been pursued in eff

94 cer marker survivin, hybridized with a short oligonucleotide bearing FRET acceptor ATTO647N.

95 d polymers with designer properties, such as oligonucleotide binding.

96 ZF) sub-ring followed by the oligosaccharide/oligonucleotide-binding (OB) fold ring.

97 ed to simple mixtures of lysates with linear oligonucleotides both in vitro and in vivo, and reduce t

98 nal 3D hydrogels engineered from peptide and oligonucleotide building blocks to provide sequence-spec

99 y structure (hydrogen bonding status) of the oligonucleotides, but neither on their charge state nor

100 After synthesis of an RNA-DNA oligonucleotide by DNA polymerase alpha holoenzyme, prol

101 how that N6-methyl deoxyadenosine-containing oligonucleotides can be enriched from complex mixtures,

102 ticles (MOF NPs) densely functionalized with oligonucleotides can be programmed to crystallize into a

103 Oligonucleotides can be used to modulate gene expression

104 l elements into transcription factor binding oligonucleotides can enhance specificity and affinity.

105 NA single strand is folded by many short DNA oligonucleotides, can be employed to make objects compri

106 ier and enable topical delivery of antisense oligonucleotides capable of specifically targeting infla

107 following hybridization with target-specific oligonucleotide capture probes.

108 ever, it is requisite to rigorously optimise oligonucleotide chemistries as well as chemical modifica

109 le yet highly sensitive platform to optimise oligonucleotide chemistries as well as chemical modifica

110 ific blocking of EJC deposition by antisense oligonucleotides circumvents aberrant NMD promoted by mu

111 This new oligonucleotide class provides a powerful tool for antis

112 the formation of antigen-antibody and ssDNA/oligonucleotide-complementary strand complexes in immuno

113 crystal structures of 5' and 3' exonuclease oligonucleotide complexes with 5'-(R)- and 5'-(S)-C-meth

114 DP-43 are neurotoxic and that treatment with oligonucleotides composed of TDP-43 target sequences pre

115 ynamic stability and nuclease sensitivity of oligonucleotides composed of the d(CGA) motif and severa

116 esized a series of m4C and m42C modified RNA oligonucleotides, conducted their base pairing and bioac

117 NF-kappaB inhibitor using an miR-146a mimic oligonucleotide conjugated to a scavenger receptor/Toll-

118 H19 RNA oligonucleotides conjugated with agrin (AGR-H19) and nif

119 esolution imaging using previously validated oligonucleotide constructs with slight modifications.

120 terase catalytic activity toward a 5-mer RNA oligonucleotide containing a 2',3'-cyclic phosphate grou

121 coli strains using multiple single-stranded oligonucleotides containing homological and heterologica

122 es can be chemically coupled to yield stable oligonucleotides containing N3'->P5' phosphoramidate (NP

123 A non-oligonucleotide-containing compound was designed from se

124 ed digital data archival system to study the oligonucleotide copy unevenness problem and show that th

125 hybridization with biotinylated sense-strand oligonucleotides coupled to streptavidin magnetic beads.

126 The SNAs comprise immunostimulatory oligonucleotides (CpG-1826) as adjuvants and encapsulate

127 of an intrathecally delivered SMN-enhancing oligonucleotide currently in use.

128 ed to show that binding of the single-strand oligonucleotide d[TTAGGGTTAG] to POT1 is both fast (80 m

129 Further work could bring antisense oligonucleotides, deep brain stimulation, and gene thera

130 pping in these transcripts through antisense oligonucleotide delivery in wild-type islets reduces glu

131 technological advances, achieving efficient oligonucleotide delivery, particularly to extrahepatic t

132 olide, as well as those of AvaR1 bound to an oligonucleotide derived from its operator.

133 S-PKK-L(Rx) is a ligand-conjugated antisense oligonucleotide designed for receptor-mediated delivery

134 noparticle conjugates, where multiple unique oligonucleotides displayed on a nanoparticle form a mult

135 rporate exogenously supplied single-stranded oligonucleotide donor (ssODN) at the DNA break site.

136 e dual sgRNA approach with a single-stranded oligonucleotide donor is highly specific for the Gaa(c.1

137 With 12 oligonucleotide drugs reaching the market to date and hu

138 cations for myriad indications, with several oligonucleotide drugs recently gaining approval.

139 Finally, we summarize antisense oligonucleotide drugs that have already been approved by

140 or bioconjugation of peptides, proteins, and oligonucleotides employing Michael addition and Diels-Al

141 Importantly, DNG oligonucleotides exhibit robust unaided cellular uptake

142 demand, while stable pre-activated precursor oligonucleotides expand the scope of the ligation reacti

143 the PS backbone, nucleobase composition and oligonucleotide flexibility to protein binding.

144 ecificity, and we cage a biostable antisense oligonucleotide for time-release activation and titratio

145 orm is used to design two long gene-specific oligonucleotides for PCR with generic template cassettes

146 uorophore- and fluorescence-quencher-coupled oligonucleotides for the quantitative determination of a

147 rved in humans and designed custom antisense oligonucleotides for these candidate targets.

148 However, the suitability of antisense oligonucleotides for treatment of DDEB remains unexplore

149 Whereas short telomeric oligonucleotides form a G-hairpin, their longer counterp

150 netic polymers were random sequence chimeric oligonucleotides formed by untemplated polymerization, b

151 cs and provide an update on FDA approvals of oligonucleotides from 2017 until the second quarter of 2

152 tion of 2',3'-cyclic phosphate RNA mono- and oligonucleotides from monophosphorylated precursors in f

153 After DNA sandwich hybridization, oligonucleotide-functionalized gold nanoparticles (AuNPs

154 ly reverse transcribed but to which a second oligonucleotide handle, necessary for subsequent whole t

155 six of the seven purified A3 member enzymes, oligonucleotides having 5'TC3' or 5'CT3' dinucleotide ta

156 analytical method was developed by combining oligonucleotide hybridization and LC-MS/MS technologies.

157 magnetic beads, after enzymatic extension of oligonucleotides hybridized to selected genomic regions.

158 nanoparticles conjugated to miRNA-targeting oligonucleotides in a mouse model of T1D.

159 ojected onto the tissue sample to release PC oligonucleotides in any spatial pattern across a region

160 of a single dose of Plp1-targeting antisense oligonucleotides in postnatal jimpy mice fully restored

161 es Hv1, impaired mouse pDC activation by CpG oligonucleotides in vitro and in vivo, reducing IFN-alph

162 entalizing and assembling microarray-derived oligonucleotides in vortexed emulsions.

163 erebroventricular injection of two antisense oligonucleotides in wild-type mice leads to a dose-depen

164 oying a 3'-amino group at the 3'-end of each oligonucleotide, in combination with an N-alkyl imidazol

165 affolds for the detection of single-stranded oligonucleotides, in particular microRNAs (or miRs).

166 to have all of the functional repertoire of oligonucleotides, including inducing enzymatic degradati

167 Finally, doxorubicin combination with an oligonucleotide inhibiting ECT2-Ex5 inclusion reduced do

168 zed, synthetic locked nucleic acid antisense oligonucleotide inhibitor (antimiR-132).

169 functional in vivo therapeutic screen using oligonucleotide inhibitors.

170 We also demonstrate the formation of long oligonucleotides inside model prebiotic vesicles, which

171 on, we show here that the programmability of oligonucleotide interactions allows the modulus of DNA-g

172 ew assay for tracking assembly of N with RNA oligonucleotides into NCLPs.

173 into the backbone such that a full PS 16-mer oligonucleotide is comprised of 215 distinct stereoisome

174 nes from minimally modified 3'- and 5'-amino oligonucleotides is described.

175 e activity, which enables cleavage of an RNA oligonucleotide labeled with a quencher/fluorophore pair

176 Treatment with RIPK1 antisense oligonucleotides led to a reduction in aortic sinus and

177 y, selective TGLI1 knockdown using antisense oligonucleotides led to decreased breast cancer brain me

178 acterize RNA modifications at nucleoside and oligonucleotide levels.

179 nables the isolation of aptamers from random oligonucleotide libraries.

180 lt and pediatric GBM cells using a synthetic oligonucleotide library representing all known human mic

181 ion of SphK1 in pDCs mitigates uptake of CpG oligonucleotide ligands by TLR9 ligand.

182 participants (1:1) to either PDR testing by oligonucleotide ligation assay (OLA) to guide selection

183 However, the replication of oligonucleotides long enough to encode catalytic functio

184 The chemical replication of oligonucleotides long enough to perform catalytic functi

185 ide preliminary baseline metrics for current oligonucleotide manufacturing processes.

186 responsible for these effects, as antisense oligonucleotide-mediated inhibition of Malat1 also suppr

187 rotic mice during apolipoprotein B antisense oligonucleotide-mediated lipid lowering.

188 s from isocratic and gradient separations of oligonucleotides (model compounds) were evaluated by sto

189 An efficient and scalable synthesis of new oligonucleotide monomers was developed for replacement o

190 Overall, we present an oligonucleotide MS method which is broadly applicable to

191 These newly derived oligonucleotides named malaswitches bind their cognate f

192 report the development of a splice-switching oligonucleotide, named SSO Ex5, that lowers the 607:558

193 try, topically applied, spherically arranged oligonucleotide nanoconjugates (spherical nucleic acids

194 Treatment with the antisense oligonucleotide nusinersen has been shown to improve mot

195 le in the presence of 5'-exonuclease than an oligonucleotide of the same sequence and chemical compos

196 in situ hybridization using probes based on oligonucleotides (oligo-FISH) is a useful tool for chrom

197 probes to target small RNAs that combine DNA oligonucleotides (oligos) for PAINT with LNA-containing

198 ction of FISH probes entirely from synthetic oligonucleotides (oligos), allowing the optimization of

199 We focus on synthetic brush polymers of oligonucleotides, oligosaccharides, and oligopeptides, p

200 y developing a strategy to spatially pattern oligonucleotides on a nanoparticle, we demonstrate that

201 ugar modifications in tandem to create novel oligonucleotide (ON) analogues that are hitherto unexplo

202 l tool to study the modification state of an oligonucleotide (ON) in a sensitive manner.

203 e method using either chemically synthesized oligonucleotides or amplicon-based single-stranded DNA p

204 Knockdown of msmb3 with antisense morpholino oligonucleotides or disruption of msmb3 by CRISPR/Cas9 b

205 As artificial RNA oligonucleotides or single-stranded DNA with receptor an

206 t high cost by expensive custom synthesis of oligonucleotides, or through use of proprietary library

207 actor using changes in concentrations of DNA oligonucleotide outputs.

208 Oligonucleotides, peptides, and peptide nucleic acids in

209 Further, Csx3 harbors cyclic oligonucleotide phosphodiesterase activity that quickly

210 Nature has three biopolymers: oligonucleotides, polypeptides, and oligosaccharides.

211 tereospecific synthesis of methylphosphonate oligonucleotide precursors.

212 e of DNA brick nanostructures with dendritic oligonucleotides prevents nuclease digestion.

213 plification utilizing energy-transfer-tagged oligonucleotide probes provides a highly sensitive and s

214 icroarrays (DNA chips) with species-specific oligonucleotide probes represent a rapid alternative to

215 and engineering improvements that would make oligonucleotide production more sustainable.

216 development, the current state of the art in oligonucleotide production poses a waste and cost burden

217 in understanding phosphorothioate antisense oligonucleotide (PS-ASO) interactions with proteins has

218 Release of phosphorothioate antisense oligonucleotides (PS-ASOs) from late endosomes (LEs) is

219 Determination of phosphorothioate oligonucleotide purity and impurity profile is commonly

220 We use oligonucleotide reaction networks, photolithography, and

221 Oligonucleotide recognition occurs through an appended S

222 Modified oligonucleotides represent a promising avenue for drug d

223 Peritumoral administration of u-oligonucleotide results in its rapid distribution and ef

224 rotein selectively or to a complementary DNA oligonucleotide reversibly using toehold-mediated DNA st

225 Peptidyl-oligonucleotide ribonucleases are here chemically engine

226 ple strategy for the synthesis of main chain oligonucleotide rotaxanes with precise control over the

227 enable construction of sulfonamide antisense oligonucleotides (SaASOs).

228 easures chromatin accessibility of synthetic oligonucleotide sequence libraries integrated into a con

229 en derived from a droplet with more than one oligonucleotide sequence, which we call "barcode multipl

230 ter distinction against single-base mismatch oligonucleotide sequences compared to the competitive on

231 nsive table of candidate pegRNAs, along with oligonucleotide sequences for cloning.

232 Aptamers are oligonucleotide sequences that can be evolved to bind to

233 store digital data by encoding 12 unique DNA oligonucleotide sequences with video game music, which i

234 ting systems rely on presynthesis of (short) oligonucleotide sequences, self-replication in the prese

235 ate 2'-5'- and 3'-5'-linked bacterial cyclic oligonucleotide signals and enable specific recognition

236 ntibodies) or new modalities (e.g. antisense oligonucleotides, siRNA or PROTAC), feasibility (availab

237 restoring hope that a new era has dawned in oligonucleotide/siRNA clinical therapeutics.

238 3, a clinically applicable, potent antisense oligonucleotide specifically targeting exon 73.

239 paramagnetic resonance (EPR) spectroscopy of oligonucleotides spin-labelled with triazole-appended ni

240 n situ as the concentration of an output DNA oligonucleotide strand.

241 DNA nanotechnology uses oligonucleotide strands to assemble molecular structures

242 Based on these observations, we designed oligonucleotides strongly potentiating TLR8 sensing of R

243 is an attractive means for the regulation of oligonucleotide structure as it can be delivered with hi

244 rst human trial of an HTT-lowering antisense oligonucleotide successfully, and safely, reduced the CS

245 A first-in-class HK2 antisense oligonucleotide suppresses HK2 expression in cell cultur

246 Liquid-phase oligonucleotide synthesis (LPOS) uses soluble polymer su

247 Solid-phase oligonucleotide synthesis (SPOS) based on phosphoramidit

248 tive, we summarize the present challenges in oligonucleotide synthesis, purification, and isolation;

249 unately, novel genetic technologies-scalable oligonucleotide synthesis, RNA sequencing, and CRISPR (c

250 orporated into DNA and RNA, respectively, by oligonucleotide synthesis.

251 eins or RNAs using oligonucleotide tags; (2) oligonucleotide tags attached to affinity reagents (anti

252 ultiplexed readout of proteins or RNAs using oligonucleotide tags; (2) oligonucleotide tags attached

253 ive growth of glioma, we find that antisense oligonucleotides targeting lncGRS-1 selectively decrease

254 Antisense oligonucleotides targeting multiple types of non-product

255 Antisense oligonucleotides targeting the same lncRNAs exhibited gl

256 The ability of multiple exogenous small oligonucleotides targeting VZVsncRNA to inhibit VZV repl

257 via the first example of an electrochemical oligonucleotide-templated reaction (EOTR), whereby two P

258 ybrid material has a higher bulk affinity to oligonucleotides than peptides composed exclusively of c

259 by incorporating a short, typically labeled oligonucleotide that is complementary to the analyte-bin

260 Tofersen is an antisense oligonucleotide that mediates the degradation of superox

261 The design of modified oligonucleotides that combine in one molecule several th

262 Oligonucleotides that consist entirely of TMO linkages a

263 red three approaches to the design of splint oligonucleotides that enable efficient ligation but whic

264 ps (RAIL), utilizes complementary helper DNA oligonucleotides that expose gaps or loops at selected p

265 al of this strategy, we identified antisense oligonucleotides that stably decrease the levels of Plp1

266 encapsulating an array of immunostimulatory oligonucleotides that, in some cases, greatly increase t

267 elution modes demonstrated that for smaller oligonucleotides the number of binding sites remained un

268 Here, we review the field of oligonucleotide therapeutics and provide an update on FD

269 juvants, including CpG ODN 2006, a synthetic oligonucleotide TLR9 ligand (TLR9L).

270 t advances, targeted delivery of therapeutic oligonucleotide to extra-hepatic tissues continues to be

271 ch were edited with TALENs and single-strand oligonucleotide to introduce a P663-L663 substitution in

272 zers, BePI and coralyne, and a complementary oligonucleotide to mimic a destabilizer, MCRa2.

273 istration of a locked nucleic acid antisense oligonucleotide to young-adult aspartoacylase-deficient

274 emically conjugating short linear strands of oligonucleotides to a nanoparticle template.

275 istered weekly injections of RIPK1 antisense oligonucleotides to Apoe(-/-) mice fed a cholesterol-ric

276 mically labeled by attaching identifying DNA oligonucleotides to cellular proteins.

277 We show the use of 5'-Acrydite oligonucleotides to copolymerize single-cell DNA or RNA

278 Titration of small ssDNA oligonucleotides to Mycobacterium smegmatis topoisomeras

279 nally, we develop splice-switching antisense oligonucleotides to reverse the increased skipping of TR

280 t uses patterned illumination and photocaged oligonucleotides to serially print barcodes ('zipcodes')

281 scherichia coli using mutant single-stranded oligonucleotides to target PCR-derived linear double-str

282 erting astrocytes to neurons using antisense oligonucleotides to transiently suppress PTB.

283 Joining oligonucleotides together (ligation) is a powerful means

284 increase in memory development, as both CpG oligonucleotide treatment or cotransfer of wild-type and

285 and its inhibition with antisense morpholino oligonucleotides (U1 AMO) triggers widespread premature

286 ach creates a new problem because the splint oligonucleotides used to drive ribozyme assembly strongl

287 ective delivery of TRIM37-specific antisense oligonucleotides using antifolate receptor 1-conjugated

288 ding blocks, as well as the assembly of long oligonucleotides using short splint oligonucleotides.

289 pe of modified mesyl phosphoramidate (or u-) oligonucleotide was described that demonstrates high aff

290 th pressure rise while an increase for large oligonucleotides was observed, indicating their alignmen

291 g experiments with fluorescently labeled DNA oligonucleotides, we tested whether the ability of ScRim

292 Four decades have passed since oligonucleotides were first used to manipulate gene expr

293 Antisense morpholino oligonucleotides were targeted to Ct-Smad2/3 and Ct-Smad

294 Antisense oligonucleotides were used to inhibit miRNAs.

295 ligation can assemble long RNAs from shorter oligonucleotides, which would be easier to replicate.

296 An Oligonucleotide with ANA at the 5' end was more stable i

297 probe is a single fluorophore-tagged hairpin oligonucleotide with five continuous ribonucleotides whi

298 RNA oligonucleotides with a single incorporated zebularine a

299 nylated locked nucleic acid (LNA)-containing oligonucleotides with toehold architecture capable of hy

300 ed cellular uptake as compared to unmodified oligonucleotides without apparent cellular toxicity.